New migraine combo drug passes early safety check
NCT ID NCT06578585
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study looked at whether it is safe to take the experimental drug Lu AG09222 together with the approved migraine pill ubrogepant. 43 adults with migraine received both treatments or a placebo injection. The main goal was to track any side effects, not to measure how well the drugs work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Neuroscience Solutions
Orlando, Florida, 32801, United States
-
Elevate Clinical Research
Seabrook, Texas, 77586, United States
-
Future Search Trials
Austin, Texas, 78731, United States
-
NeuroTrials Research
Atlanta, Georgia, 30328, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Experimental migraine drug JS010 takes first step in human safety trial
- Scientists probe shared pain pathways in endometriosis and migraine
- Brain scans and heat tests may predict migraine in teens
- Could a simple diary ease the burden of migraine?